Concr Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
15
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
19
Concr General Information
Description
Developer of a cloud-based therapeutic platform designed to improve cancer treatment through the prediction of patients' responses. The company's platform identifies optimal treatment for an individual, reduces treatment resistance, and offers patient-specific cancer progression and evidence-based personalized treatment plans, enabling users to proactively adapt treatment before it becomes ineffective.
Contact Information
Website
www.concr.coCorporate Office
- Regent House
- 316a Beulah Hill
- London SE19 3HF
- England, United Kingdom
Corporate Office
- Regent House
- 316a Beulah Hill
- London SE19 3HF
- England, United Kingdom
Concr Timeline
Concr Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Accelerator/Incubator | 01-Jan-2025 | Completed | Generating Revenue | |||
| 5. Later Stage VC | 12-Aug-2024 | Completed | Generating Revenue | |||
| 4. Seed Round | 01-Nov-2023 | Completed | Generating Revenue | |||
| 3. Seed Round | 05-Oct-2022 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | 24-Sep-2020 | $13.1K | $13.1K | Completed | Startup | |
| 1. Accelerator/Incubator | 10-Dec-2019 | Completed | Startup |
Concr Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 293,229 | $0.000129 | $2.19 | $2.19 | 1x | $2.19 | 11.28% | |
| Ordinary | 236,269 | $0.000129 | $1.33 | $1.33 | 1x | $1.33 | 9.09% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Concr Comparisons
Industry
Financing
Details
Concr Competitors (3)
One of Concr’s 3 competitors is Genialis, a Venture Capital-Backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Genialis | Venture Capital-Backed | Boston, MA | ||||
| OncoHost | Venture Capital-Backed | Cary, NC | ||||
| Cyted Health | Venture Capital-Backed | Cambridge, United Kingdom |
Concr Signals
Concr Investors (19)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BioIndustry Association | Accelerator/Incubator | Minority | ||
| Blue Falcon Capital | Venture Capital | Minority | ||
| Cambridge Enterprise Ventures | Venture Capital | Minority | ||
| Debiopharm Innovation Fund | Corporate Venture Capital | Minority | ||
| Innovate UK | Government | Minority |
Concr FAQs
-
When was Concr founded?
Concr was founded in 2018.
-
Where is Concr headquartered?
Concr is headquartered in London, United Kingdom.
-
What is the size of Concr?
Concr has 15 total employees.
-
What industry is Concr in?
Concr’s primary industry is Therapeutic Devices.
-
Is Concr a private or public company?
Concr is a Private company.
-
What is Concr’s current revenue?
The current revenue for Concr is .
-
How much funding has Concr raised over time?
Concr has raised $4.64M.
-
Who are Concr’s investors?
BioIndustry Association, Blue Falcon Capital, Cambridge Enterprise Ventures, Debiopharm Innovation Fund, and Innovate UK are 5 of 19 investors who have invested in Concr.
-
Who are Concr’s competitors?
Genialis, OncoHost, and Cyted Health are competitors of Concr.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process